How to assess treatment efficacy in Sjögrens syndrome?

Current Opinion in Rheumatology

Volumn 24, Issue 3, 2012, Pages 281-289

  Vissink, Arjan ^a   Bootsma, Hendrika ^a   Kroese, Frans G M ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

biologicals; ESSDAI; ESSPRI; saliva; Sj gren's syndrome; tears; treatment efficacy

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN G; RHEUMATOID FACTOR; RITUXIMAB;

BLOOD SAMPLING; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; LACRIMAL GLAND FUNCTION; PRIORITY JOURNAL; REVIEW; SALIVA ANALYSIS; SALIVARY GLAND BIOPSY; SIALOGRAPHY; SJOEGREN SYNDROME; ULTRASOUND;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; PROGNOSIS; SALIVA; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TEARS; TREATMENT OUTCOME;

EID: 84859243612     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283524c37     Document Type: Review

References (80)

1. Kalk WW, Mansour K, Vissink A, et al. Oral and ocular manifestations in Sjögren's syndrome. J Rheumatol 2002; 29:924-930 (Pubitemid 34493494)
2. Fox RI. Sjö gren's syndrome. Lancet 2005; 366:321-331
3. Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-related quality of life, employment and disability in patients with Sjö gren's syndrome. Rheumatology (Oxford) 2009; 48:1077-1082
4. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165:2337-2344 (Pubitemid 41640845)
5. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjö gren's syndrome: clinical and pathophysiologic aspects.Medicine (Baltimore) 2009; 88:284-293
6. Kallenberg CG, Vissink A, Kroese FG, et al. What have we learned from clinical trials in primary Sjö gren's syndrome about pathogenesis? Arthritis Res Ther 2011; 13:205.
7. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjö gren syndrome: a systematic review. JAMA 2010; 304:452-460.
8. Meiners PM, Vissink A, Kallenberg CG, et al. Treatment of primary Sjö gren's syndrome with anti-CD20 therapy (rituximab): a feasible approach or just a starting point? Expert Opin Biol Ther 2011; 11:1381-1394.
9. Van der Reijden WA, Van der Kwaak H, Vissink A, et al. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjö gren's syndrome. Arthritis Rheum 1996; 39:57-63
10. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjö gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999; 159:174-181 (Pubitemid 29055106)
11. Hansen A, Dörner T. Current therapeutic options in Sjögren's syndrome [in German]. Z Rheumatol 2010; 69:19-24
12. Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 2010; 62:551-558.
13. Seror R, Ravaud P, Bowman S, et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjögren's syndrome. Ann Rheum Dis 2010; 69:1103-1109.
14. Bowman SJ, Pillemer S, Jonsson R, et al. Contributors to and participants at the workshop. Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology (Oxford) 2001; 40:1180-1188
15. Asmussen KH, Bowman SJ. Outcome measures in Sjögren's syndrome. Rheumatology (Oxford) 2001; 40:1085-1088
16. Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjögren's syndrome, April 10-11, 20#03, Bethesda, Maryland, USA. J Rheumatol 2005; 32:143-149
17. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740-2750 (Pubitemid 41369102)
18. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66:351-357 (Pubitemid 46579637)
19. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57:310-317 (Pubitemid 47164095)
20. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541-1544
21. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68:284-285
22. Ramos-Casals M, Garća-Hernández FJ, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28:468-476
23. Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005; 64:958-960 (Pubitemid 40733928)
24. Meijer JM, Meiners PM, Vissink A, et al. Effective rituximab treatment in primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:960-968.
25. Seror R, Ravaud P, Mariette X, et al. EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann Rheum Dis 2011; 70:968-972.
26. Gossec L, Paternotte S, Aanerud GJ, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Rheum Dis 2011; 70:935-942
27. Luijten KM, Tekstra J, Bijlsma JW, et al. The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2011 [Epub ahead of print]
28. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40:171-178 (Pubitemid 17007065)
29. Fortin PR, Stucki G, Katz JN. Measuring relevant change: an emerging challenge in rheumatologic clinical trials. Arthritis Rheum 1995; 38:1027-1030
30. Campar A, Isenberg DA. Primary Sjögren's syndrome activity and damage indices comparison. Eur J Clin Invest 2010; 40:636-644
31. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis 2012 [Epub ahead of print].
32. Mignogna MD, Fedele S, Lo Russo L, et al. Sjögren's syndrome: the diagnostic potential of early oral manifestations preceding hyposalivation/ xerostomia. J Oral Pathol Med 2005; 34:1-6 (Pubitemid 40142922)
33. Kalk WW, Vissink A, Spijkervet FK, et al. Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome. Ann Rheum Dis 2001; 60:1110-1116 (Pubitemid 33096075)
34. Kalk WW, Vissink A, Stegenga B, et al. Sialometry and sialochemistry: a noninvasive approach for diagnosing Sjögren's syndrome. Ann Rheum Dis 2002; 61:137-144 (Pubitemid 34098429)
35. Pijpe J, Kalk WW, Bootsma H, et al. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. Ann Rheum Dis 2007; 66:107-112 (Pubitemid 46044868)
36. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum 2009; 60:3251-3256
37. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-558 (Pubitemid 34539104)
38. Atkinson JC, Travis WD, Pillemer SR, et al. Major salivary gland function in primary Sjögren's syndrome and its relationship to clinical features. J Rheumatol 1990; 17:318-322 (Pubitemid 20106608)
39. Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjögren's syndrome. BMC Clin Pathol 2005; 5:4
40. Ryu OH, Atkinson JC, Hoehn GT, et al. Identification of parotid salivary biomarkers in Sjögren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology (Oxford) 2006; 45:1077-1086 (Pubitemid 44542092)
41. Hu S, Wang J,Meijer JM, et al. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 2007; 56:3588-3600 (Pubitemid 350100692)
42. Ferraccioli G, De Santis M, Peluso G, et al. Proteomic approaches to Sjögren's syndrome: a clue to interpret the pathophysiology and organ involvement of the disease. Autoimmun Rev 2010; 9:622-626
43. Hu S, Gao K, Pollard R, et al. Preclinical validation of salivary biomarkers for primary Sjögren's syndrome. Arthritis Care Res 2010; 62:1633-1638.
44. Hu S, Vissink A, Arellano M, et al. Identification of autoantibody biomarkers for primary Sjögrens syndrome using protein microarrays. Proteomics 2010; 11:1499-1507. This study de
45. Xiao H, Wong DT. Proteomics and its applications for biomarker discovery in human saliva. Bioinformation 2011; 5:294-296
46. Baldini C, Giusti L, Bazzichi L, et al. Proteomic analysis of the saliva: a clue for understanding primary from secondary Sjögren's syndrome? Autoimmun Rev 2008; 7:185-191
47. Hu S, Zhou M, Jiang J, et al. Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. Arthritis Rheum 2009; 60:81-92
48. Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, et al. Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: quantitative and Doppler waveform analysis. Biologics 2007; 1:311-319
49. Wernicke D, Hess H, Gromnica-Ihle E, et al. Ultrasonography of salivary glands: a highly specific imaging procedure for diagnosis of Sjögren's syndrome. J Rheumatol 2008; 35:285-293 (Pubitemid 351281150)
50. Salaffi F, Carotti M, Iagnocco A, et al. Ultrasonography of salivary glands in primary Sjögren's syndrome: a comparison with contrast sialography and scintigraphy. Rheumatology (Oxford) 2008; 47:1244-1249 (Pubitemid 352038236)
51. Milic VD, Petrovic RR, Boricic IV, et al. Diagnostic value of salivary gland ultrasonographic scoring system in primary Sjögren's syndrome: a comparison with scintigraphy and biopsy. J Rheumatol 2009; 36:1495-1500
52. Takagi Y, Kimura Y, Nakamura H, et al. Salivary gland ultrasonography: can it be an alternative to sialography as an imaging modality for Sjögren's syndrome? Ann Rheum Dis 2010; 69:1321-1324.
53. Obinata K, Sato T, Ohmori K, et al. A comparison of diagnostic tools for Sjögren syndrome, with emphasis on sialography, histopathology, and ultrasonography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:129-134.
54. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974; 37:217-229
55. Daniels TE, Whitcher JP. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjögren's syndrome. Arthritis Rheum 1994; 37:869-877
56. Lindahl G, Hedfors E. Focal lymphocytic infiltrates of salivary glands are not confined to Sjögren's syndrome. Scand J Rheumatol Suppl 1986; 61:52-55 (Pubitemid 17120328)
57. Pijpe J, Kalk WW, van der Wal JE, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2007; 46:335-341 (Pubitemid 46189797)
58. Ihrler S, Zietz C, Sendelhofert A, et al. Lymphoepithelial duct lesions in Sjögren-type sialadenitis. Virchows Arch 1999; 434:315-323 (Pubitemid 29201834)
59. Marx RE, Hartman KS, Rethman KV. A prospective study comparing incisional labial to incisional parotid biopsies in the detection and confirmation of sarcoidosis, Sjögren's disease, sialosis and lymphoma. J Rheumatol 1988; 15:621-629
60. Pollard RP, Pijpe J, Bootsma H, et al. Treatment of MALT lymphoma in Sjögren's syndrome: a retrospective clinical study. J Rheumatol 2011; 38:2198-2208.
61. Van Mello NM, Pillemer SR, Tak PP, Sankar V. B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sjögren's syndrome. Ann Rheum Dis 2005; 64:471-473 (Pubitemid 40283062)
62. Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011; 70:1363-1368.
63. Fox RI. The importance of minor salivary gland biopsy in prediction of lymphoma in Sjögren's syndrome: should we be obtaining more information about prognosis from minor salivary gland samples? Ann Rheum Dis 2011; 70:1351-1353.
64. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151:792-798.
65. Utine CA, Bçakçgil M, Yavuz S, Çiftçi F. Tear osmolarity measurements in dry eye related to primary Sjögren's syndrome. Curr Eye Res 2011; 36:683-690.
66. Utine JK, Kim MK, Wee WR. Prognostic factors for the clinical severity of keratoconjunctivitis sicca in patients with Sjögren's syndrome. Br J Ophthalmol 2012; 96:240-245.
67. Nguyen CQ, Peck AB. Unraveling the pathophysiology of Sjögren syndromeassociated dry eye disease. Ocul Surf 2009; 7:11-27
68. Tomosugi N, Kitagawa K, Takahashi N, et al. Diagnostic potential of tear proteomic patterns in Sjögren's syndrome. J Proteome Res 2005; 4:820-825 (Pubitemid 40863270)
69. Karns K, Herr AE. Human tear protein analysis enabled by an alkaline microfluidic homogeneous immunoassay. Anal Chem 2011; 83:8115-8122.
70. Toda I. Autoantigens and Sjögren syndrome. Cornea 2002; 21 (2 Suppl. 1): S13-S16
71. Dubucquoi S. Antialpha-fodrin antibodies: interest for the diagnosis of Sjögren's syndromes [in French]. Rev Med Interne 2005; 26:85-87 (Pubitemid 40260511)
72. Potthoff A, Witte T, Rifai K, et al. Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjögren syndrome. Scand J Gastroenterol 2009; 44:994-1003
73. Backman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. Invest Ophthalmol Vis Sci 2001; 42:321-327 (Pubitemid 32121458)
74. Reina S,Orman B, Anaya JM, et al. Cholinoreceptor autoantibodies in Sjögren syndrome. J Dent Res 2007; 86:832-836
75. Appel S, Le Hellard S, Bruland O, et al. Potential association of muscarinic receptor 3 gene variants with primary Sjögren's syndrome. Ann Rheum Dis 2011; 70:1327-1329
76. Brito-Zerón P, Ramos-Casals M, Nardi N, et al. Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients. Medicine (Baltimore) 2005; 84:90-97 (Pubitemid 40418637)
77. Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjögren's syndrome patients. Clin Rev Allerg Immunol 2007; 32:265-274 (Pubitemid 350242572)
78. Zadura AF, Theander E, Blom AM, Trouw LA. Complement inhibitor C4bbinding protein in primary Sjögren's syndrome and its association with other disease markers. Scand J Immunol 2009; 69:374-380
79. Wu T, Mohan C. Proteomic toolbox for autoimmunity research. Autoimmun Rev 2009; 8:595-598
80. Kimoto O, Sawada J, Shimoyama K, et al. Activation of the interferon pathway in peripheral blood of patients with Sjögren's syndrome. J Rheumatol 2011; 38:310-316.